Risk factors associated with increased discontinuation rate of trimethoprim-sulfamethoxazole used as a primary prophylaxis for Pneumocystis pneumonia: A retrospective cohort study.

[1]  J. Sensakovic,et al.  Trimethoprim-sulfamethoxazole , 2021, The Medical clinics of North America.

[2]  H. Kikuchi,et al.  Efficacies of atovaquone, pentamidine, and trimethoprim/sulfamethoxazole for the prevention of Pneumocystis jirovecii pneumonia in patients with connective tissue diseases. , 2019, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[3]  You-ning Liu,et al.  Penetration of Ciprofloxacin and Amikacin into the Alveolar Epithelial Lining Fluid of Rats with Pulmonary Fibrosis , 2017, Antimicrobial Agents and Chemotherapy.

[4]  M. Tomita,et al.  Optimal regimens of sulfamethoxazole-trimethoprim for chemoprophylaxis of Pneumocystis pneumonia in patients with systemic rheumatic diseases: results from a non-blinded, randomized controlled trial , 2017, Arthritis Research & Therapy.

[5]  O. Decaux,et al.  Incidence of Pneumocystis jiroveci pneumonia among groups at risk in HIV-negative patients. , 2014, The American journal of medicine.

[6]  L. Leibovici,et al.  Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients. , 2014, The Cochrane database of systematic reviews.

[7]  M. Tsai,et al.  Multicenter Study of Trimethoprim/Sulfamethoxazole-Related Hepatotoxicity: Incidence and Associated Factors among HIV-Infected Patients Treated for Pneumocystis jirovecii Pneumonia , 2014, PloS one.

[8]  Yang Zhao,et al.  Intrapulmonary concentration of levofloxacin in patients with idiopathic pulmonary fibrosis. , 2014, Pulmonary pharmacology & therapeutics.

[9]  Glen R. Brown.  Cotrimoxazole - optimal dosing in the critically ill , 2014, Annals of Intensive Care.

[10]  Yoshiya Tanaka,et al.  Prophylaxis for Pneumocystis pneumonia in patients with rheumatoid arthritis treated with biologics, based on risk factors found in a retrospective study , 2014, Arthritis Research & Therapy.

[11]  G. Nichols,et al.  Increasing Pneumocystis Pneumonia, England, UK, 2000–2010 , 2013, Emerging infectious diseases.

[12]  T. Habuchi,et al.  Influence of NAT2 Polymorphisms on Sulfamethoxazole Pharmacokinetics in Renal Transplant Recipients , 2011, Antimicrobial Agents and Chemotherapy.

[13]  A. Ishizaka,et al.  Serum indicators for the diagnosis of pneumocystis pneumonia. , 2007, Chest.

[14]  N. Kamatani,et al.  Association of the diplotype configuration at the N-acetyltransferase 2 gene with adverse events with co-trimoxazole in Japanese patients with systemic lupus erythematosus , 2007, Arthritis research & therapy.

[15]  A. Limper,et al.  Medical progress: Pneumocystis pneumonia , 2004 .

[16]  K. Tabei,et al.  Hyponatremia and/or hyperkalemia in patients treated with the standard dose of trimethoprim-sulfamethoxazole. , 2003, Internal medicine.

[17]  J. Zurlo,et al.  Trimethoprim-sulfamethoxazole revisited. , 2003, Archives of internal medicine.

[18]  K. Sepkowitz.  Opportunistic infections in patients with and patients without Acquired Immunodeficiency Syndrome. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[19]  R. Garland,et al.  Management and outcome patterns for adult Pneumocystis carinii pneumonia, 1985 to 1995: comparison of HIV-associated cases to other immunocompromised states. , 2000, Chest.

[20]  W. El-Sadr,et al.  Atovaquone compared with dapsone for the prevention of Pneumocystis carinii pneumonia in patients with HIV infection who cannot tolerate trimethoprim, sulfonamides, or both. Community Program for Clinical Research on AIDS and the AIDS Clinical Trials Group. , 1998, The New England journal of medicine.

[21]  R. Garland,et al.  Use of adjunctive corticosteroids in severe adult non-HIV Pneumocystis carinii pneumonia. , 1998, Chest.

[22]  H. Saka,et al.  Adjustment of creatinine clearance improves accuracy of Calvert's formula for carboplatin dosing. , 1997, British Journal of Cancer.

[23]  S. Spector,et al.  A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group. , 1995, The New England journal of medicine.

[24]  Y. van der Graaf,et al.  A controlled trial of aerosolized pentamidine or trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus infection. The Dutch AIDS Treatment Group. , 1992, The New England journal of medicine.

[25]  K. Sepkowitz,et al.  Pneumocystis carinii pneumonia among patients without AIDS at a cancer hospital. , 1992, JAMA.

[26]  T. Yoshikawa.  Antimicrobial Therapy for the Elderly Patient , 1990, Journal of the American Geriatrics Society.

[27]  Cockcroft Dw,et al.  Prediction of Creatinine Clearance from Serum Creatinine , 1976 .